EDAP TMS SA announced the successful treatment of the first patient in its phase I/II PULS Trial, which is investigating the use of High Intensity Focused Ultrasound (HIFU) technology for pancreatic ...

As part of Ken Cleary’s usual health checks and monitoring that are typical for a man in his 60s, he learned his level of prostate-specific antigen, or PSA, a protein that can indicate cancer, was ...

CHI Memorial is now offering high-intensity focused ultrasound (HIFU), a treatment option for prostate cancer patients. "HIFU is a revolutionary procedure designed to treat prostate cancer with ...

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S ...

LYON, France, February 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) ...

Focal therapy, including HIFU, targets only cancerous prostate areas, preserving organ function and minimizing side effects like erectile dysfunction and urinary incontinence. HIFU is suitable for ...

AMSTERDAM—High-intensity focused ultrasound (HIFU) shows promise as a treatment for early-stage prostate cancer, according to interim study results presented here at the 7 th Meeting of the European ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Investigators who conducted 2 clinical trials concluded that focal therapy is not inferior to radical prostatectomy with respect to treatment failure. Focal therapy such as high-intensity focused ...

EDAP Q4 2025 earnings call highlights: record Focal One HIFU growth, FDA clearance, reimbursement boosts and 2026 guidance.